Hengsai Biologicals Closes First Round of Strategic Financing

Recently, Hengsai Bio completed the first round of strategic financing, exclusively invested by Tensil Capital. This round of funding will be mainly used to promote the R&D and clinical trials of the core pipeline as well as the company's internationalization strategy layout. Both parties have carried out extensive and in-depth communication and planning on domestic and international project cooperation. In the future, they will give full play to their respective business advantages, take equity investment as the core link, and help Hengsai Biologicals accelerate the whole chain upgrade from technology research and development to commercialization landing through multiple modes of business synergism, resource integration and industrial empowerment.

Construction of R&D center and pilot plant in Zhongshan. The financing is jointly invested by Cuiheng Group, Xiban Investment Control, Zhongshan Venture Capital and Chengming Capital.

Mr. Ji Haibin, Managing Partner of Tianshili Capital::"It is a great honor to participate in the first round of strategic financing of Hengsai Bio! In the field of cell and gene therapy, Tianshi Capital has covered the whole industry chain of upstream and downstream enterprises through systematic layout, and constructed a complete CGT industry ecosystem covering R&D, production, service and commercialization. In the DC vaccine track, we have always been committed to joining hands with high-quality enterprises with innovation potential and core technology barriers to improve the overall industrial layout. As a global leader in DC vaccine R&D, Hengsai Bio has been highly recognized by international regulatory agencies for its product innovation, safety, efficacy and addressing unmet clinical needs. We look forward to deepening our cooperation with Hengsai Biotechnology and accelerating the early launch of its DC vaccine products for the benefit of global tumor patients!"

Dr. Liu Huining, Founder and CEO of Hengsai Biologicals Inc.::"Sincere thanks to the support and trust of Tiansi Capital! This cooperation is not only a strong combination of capital and technology, but also a model of synergistic development of industrial ecology. In the future, Hengsai Bio will rely on the all-round support of Tiansi Capital to continuously improve its core competitiveness, accelerate the transformation and application of its innovative achievements, provide more high-quality therapeutic choices for patients around the world, and work hand in hand to create a new chapter in the biopharmaceutical industry."

About Tesco Capital

TIANSILI Capital has long been committed to searching for the basic driving force of industry development, facing the world's scientific and technological frontiers, the main battlefield of the economy, the major needs of the country, and the "choke point" technologies for people's life and health, and exploring the high-quality projects that are inimitable and irreplaceable, with relatively mature technologies, promising industrial transformation, and possessing huge market space. Projects. Relying on the specialized, refined and long-term fund management team, we continue to observe the trend of structural redistribution of the industry, and form differentiated capabilities of quality track prediction, selection of underlying technology and key technology, and identification of high-quality targets. In the complex and volatile investment environment full of opportunities, we are dedicated to bringing predictable and sustainable investment returns to our investors.

About Kousai

Founded in 2018, Hengsai Bio is a scientific and technological innovative enterprise and national high-tech enterprise dedicated to the research, development and industrialization of dendritic cell vaccines (DC vaccines). The company has successfully constructed the Eco-DCVax platform, aiming to break down the technical barriers to industrialization and develop global First-in-Class high-quality DC vaccine products with independent property rights that are safe, efficient and convenient to administer. The developed product, therapeutic dendritic cell vaccine, provides a new approach and strategy for the treatment of relapsed and refractory tumors, chronic viral infections, autoimmune diseases and other diseases that are in urgent need of effective clinical treatments.